bluuebunny/crossref_metadata_2025 huggingface dataset:
From concrete quarks to QCD: a personal perspective
Authors: Llewellyn Smith Chris
Published: November 2023

The simple story line that ‘Gell-Mann and Zweig invented quarks in 1964 and the quark model was generally accepted after 1968 when deep inelastic electron scattering experiments at SLAC showed that they are real’ contains elements of the truth, but is not true. This paper describes the origins and development of the quark model until it became generally accepted in the mid-1970s, as witnessed by a spectator and some-time participant who joined the field as a graduate student in October 1964. It aims to ensure that the role of Petermann is not overlooked, and Zweig and Bjorken get the recognition they deserve, and to clarify the role of Serber.
Influences of Wind Deviation on the Ground Resultant Electric Field under Parallel Operation of 750‐kV Ultra‐High‐Voltage Alternating Current and ±800‐kV Extra‐High‐Voltage Direct Current Transmission Lines Passing through Residential Areas in a High‐Altitude Area
Authors: Liu Hui , Lang Xujun , Li Ziyang , Sun Zhibing , Huang Shilong
Published: November 2023

The formation mechanism of the resultant electric field is complex under parallel operation of extra‐high‐voltage alternating current (AC)/direct current (DC) transmission lines. However, existing methods are computationally expensive and fail to guarantee the stability and convergency of results. To solve this problem, a calculation method with nonuniform grids and varying time steps was proposed on the basis of the finite‐volume and finite‐element method for calculating the ground resultant electric field of parallel AC/DC transmission lines. The selection of the initial value of space charges and the setting of the surface charge density of conductors were also improved, which greatly enhanced the computational stability and efficiency. Then, the improved method was adopted to calculate the ground resultant electric field under parallel operation of a 750‐kV AC transmission line and a ±800‐kV DC transmission line when considering and not considering wind deviation. Results show that, when ignoring wind deviation, the normalized values of the ground resultant electric field within 6 m from the side‐phase conductor of the AC line are always less than 1 under conditions of the minimum clearances to earth of the AC and DC lines passing through a residential area stipulated in the national standards, which meets codified requirements. When considering wind deviation, instead of an increase, the calculated ground resultant electric field of parallel AC/DC lines is significantly reduced, and the weighted value is much less than the limiting value.
Table S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Table S3. Grade ≥3 Adverse Events Reported in >1 Patient [n (%)]
Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Authors: Solta Anna , Boettiger Kristiina , Kovács Ildikó , Lang Christian , Megyesfalvi Zsolt , Ferk Franziska , Mišík Miroslav , Hoetzenecker Konrad , Aigner Clemens , Kowol Christian R. , Knasmueller Siegfried , Grusch Michael , Szeitz Beáta , Rezeli Melinda , Dome Balazs , Schelch Karin
Published: November 2023

Proteomic analysis resulting from the comparison of SCLC cell lines showing synergistic or additive responses to entinostat and cisplatin therapy
Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Table S1. Representativeness of Study Participants with R/M ACC Patient Population
Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Authors: Solta Anna , Boettiger Kristiina , Kovács Ildikó , Lang Christian , Megyesfalvi Zsolt , Ferk Franziska , Mišík Miroslav , Hoetzenecker Konrad , Aigner Clemens , Kowol Christian R. , Knasmueller Siegfried , Grusch Michael , Szeitz Beáta , Rezeli Melinda , Dome Balazs , Schelch Karin
Published: November 2023

Proteomic analysis resulting from the comparison of entinostat sensitive versus resistant cell lines
Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Supplementary Material
Supplementary Figures 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Authors: Solta Anna , Boettiger Kristiina , Kovács Ildikó , Lang Christian , Megyesfalvi Zsolt , Ferk Franziska , Mišík Miroslav , Hoetzenecker Konrad , Aigner Clemens , Kowol Christian R. , Knasmueller Siegfried , Grusch Michael , Szeitz Beáta , Rezeli Melinda , Dome Balazs , Schelch Karin
Published: November 2023

Supplementary Figures S1-8
Figure S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Figure S3. Swimmer plot depicting duration of response among patients with response assessed by Choi criteria per blinded independent review committee in the efficacy evaluable population.
Figure S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Figure S2. Waterfall plot depicting tumor responses assessed by RECIST criteria per blinded independent review committee in the efficacy evaluable population.
Figure S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

Figure S1. Patient disposition diagram. RECIST, response criteria in solid tumors.
Supplementary Table S3 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Authors: Friedman Claire F. , Ravichandran Vignesh , Miller Kathryn , Vanderbilt Chad , Zhou Qin , Iasonos Alexia , Vivek Malavika , Mishra Pamela , Leitao Mario M. , Broach Vance , Sonoda Yukio , Kyi Chrisann , Zamarin Dmitriy , O'Cearbhaill Roisin E. , Konner Jason , Berger Michael F. , Weigelt Britta , Momeni Boroujeni Amir , Park Kay J. , Aghajanian Carol , Solit David B. , Donoghue Mark T.A.
Published: November 2023

Actionable oncogenic markers and the number of carriers
Supplementary Figure S6 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Authors: Friedman Claire F. , Ravichandran Vignesh , Miller Kathryn , Vanderbilt Chad , Zhou Qin , Iasonos Alexia , Vivek Malavika , Mishra Pamela , Leitao Mario M. , Broach Vance , Sonoda Yukio , Kyi Chrisann , Zamarin Dmitriy , O'Cearbhaill Roisin E. , Konner Jason , Berger Michael F. , Weigelt Britta , Momeni Boroujeni Amir , Park Kay J. , Aghajanian Carol , Solit David B. , Donoghue Mark T.A.
Published: November 2023

Supp Figure 6: Genomic Alterations of Rare Cervical Cancer Histologies. HPV, human papillomavirus; APOBEC, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide.
Supplementary Figure S5 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Authors: Friedman Claire F. , Ravichandran Vignesh , Miller Kathryn , Vanderbilt Chad , Zhou Qin , Iasonos Alexia , Vivek Malavika , Mishra Pamela , Leitao Mario M. , Broach Vance , Sonoda Yukio , Kyi Chrisann , Zamarin Dmitriy , O'Cearbhaill Roisin E. , Konner Jason , Berger Michael F. , Weigelt Britta , Momeni Boroujeni Amir , Park Kay J. , Aghajanian Carol , Solit David B. , Donoghue Mark T.A.
Published: November 2023

Supp Figure 5: Genomic Alterations by Tumor Type and Stage. A, Oncoprint depicting genomic alterations by tumor site, primary versus metastasis. B, Oncoprint depicting genomic alteration by stage at diagnosis. HPV, human papillomavirus; MSI, microsatellite instability; TMB-H, tumor mutational burden–high.
Supplementary Figure S4 from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Authors: Friedman Claire F. , Ravichandran Vignesh , Miller Kathryn , Vanderbilt Chad , Zhou Qin , Iasonos Alexia , Vivek Malavika , Mishra Pamela , Leitao Mario M. , Broach Vance , Sonoda Yukio , Kyi Chrisann , Zamarin Dmitriy , O'Cearbhaill Roisin E. , Konner Jason , Berger Michael F. , Weigelt Britta , Momeni Boroujeni Amir , Park Kay J. , Aghajanian Carol , Solit David B. , Donoghue Mark T.A.
Published: November 2023

Supp Figure 4: Lollipop mutation diagram of hotspot alterations in ERBB2, PIK3CA, and KRAS in the Memorial Sloan Kettering Cancer Center (MSK) Cervical Cancer Cohort
Supplementary Table S9 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

BRAF copynumber LOH
Supplementary Table S8 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

List Of TSGs On Chromosome 3q, 10q, and 11q
Supplementary Table S7 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

MMR-D cases
Supplementary Table S6 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Mutational frequency KRAS WT vs KRAS MUT
Supplementary Table S5 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

TP53 hotspot variant distribution
Supplementary Table S4 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

GENIE ID and PANID reference IDs for access to KRAS WT PDAC dataset
Supplementary Table S2 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Pathway Gene Lists
Supplementary Table S9 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Upregulated genes upon CSF1R blockade in pGBM patient-derived organoids
Supplementary Table S8 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Downregulated genes upon CSF1R blockade in pGBM patient-derived organoids
Supplementary Table S16 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Mutational Profile of BRAF in frame deleted organoid cases
Supplementary Table S6 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Common differentially expressed genes upon CSF1R blockade in pGBM patient-derived GAMs (downregulated)
Supplementary Table S4 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Fluorophore-conjugated secondary antibodies
Supplementary Table S14 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

MAPK pathway gene VUS analysis for oncogenicity in KRAS WT, MAPK Neg
Supplementary Table S3 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Primary antibodies for immunofluorescent stainings
Supplementary Table S13 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Pathway level comparison between KRAS WT Pancreatic cancers with and without MAPK alterations
Supplementary Table S12 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Genomic comparison between KRAS WT Pancreatic cancers with and without MAPK alterations
Supplementary Table S11 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

BRAF KRAS co-occurence
Supplementary Table S1 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Clinical overview of patients´ sample
Supplementary Table S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

BRAF alteration clonality assessment
Supplementary Table S1 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

List of genes covered in different OncoPanel versions
Supplementary Figure S9 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Dual pan-RAF and MEK inhibition demonstrates synergistic inhibition of pancreatic cancer PDOs harboring BRAF in-frame deletions
Supplementary Figure S5 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

pGBM patient-derived tumor organoids maintain cellular composition, extracellular matrix, and proliferative activity of the parental tumor.
Supplementary Figure S3 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Gene set enrichment analyses of RNA sequencing data identifies enhanced antigen presentation in GW2580 and BLZ945-treated GAMs.
Supplementary Figure S6 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

MAPK amplifications are alternative drivers in KRAS WT pancreatic cancer
Supplementary Figure S2 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Differential gene expression of BLZ945- and PLX3397-treated GAMs.
Supplementary Figure S5 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Pathway-level comparison reveals enrichment of alternative MAPK alterations in KRAS WT pancreatic cancer
Supplementary Figure S1 from Effective Reprogramming of Patient-Derived M2-Polarized Glioblastoma-Associated Microglia/Macrophages by Treatment with GW2580
Authors: Fermi Valentina , Warta Rolf , Wöllner Amélie , Lotsch Catharina , Jassowicz Lena , Rapp Carmen , Knoll Maximilian , Jungwirth Gerhard , Jungk Christine , Dao Trong Philip , von Deimling Andreas , Abdollahi Amir , Unterberg Andreas , Herold-Mende Christel
Published: November 2023

Expression levels of CSF1R, CD163 and HLA-DR
Supplementary Figure S4 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

RTK fusions detected in the pancreatic cancer cohort via both DNA-based and RNA-based analyses
Supplementary Figure S3 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Focal chromosomal alterations and oncogenic drivers differ between KRAS WT and mutant pancreatic cancer
Supplementary Figure S2 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Global survey of pancreatic cancer genomics captures known features of disease
Supplementary Figure S10 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors: Singh Harshabad , Keller Rachel B. , Kapner Kevin S. , Dilly Julien , Raghavan Srivatsan , Yuan Chen , Cohen Elizabeth F. , Tolstorukov Michael , Andrews Elizabeth , Brais Lauren K. , da Silva Annacarolina , Perez Kimberly , Rubinson Douglas A. , Surana Rishi , Giannakis Marios , Ng Kimmie , Clancy Thomas E. , Yurgelun Matthew B. , Schlechter Benjamin L. , Clark Jeffrey W. , Shapiro Geoffrey I. , Rosenthal Michael H. , Hornick Jason L. , Nardi Valentina , Li Yvonne Y. , Gupta Hersh , Cherniack Andrew D. , Meyerson Matthew , Cleary James M. , Nowak Jonathan A. , Wolpin Brian M. , Aguirre Andrew J.
Published: November 2023

Additional clinicopathologic/genomic data for KRAS WT patient with SLC4A4-ROS1 fusion
Supplementary Table 5 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Authors: Paolino Jonathan , Dimitrov Boris , Apsel Winger Beth , Sandoval-Perez Angelica , Rangarajan Amith Vikram , Ocasio-Martinez Nicole , Tsai Harrison K. , Li Yuting , Robichaud Amanda L. , Khalid Delan , Hatton Charlie , Gillani Riaz , Polonen Petri , Dilig Anthony , Gotti Giacomo , Kavanagh Julia , Adhav Asmani A. , Gow Sean , Tsai Jonathan , Li Yen Der , Ebert Benjamin L. , Van Allen Eliezer M. , Bledsoe Jacob , Kim Annette S. , Tasian Sarah K. , Cooper Stacy L. , Cooper Todd M. , Hijiya Nobuko , Sulis Maria Luisa , Shukla Neerav N. , Magee Jeffrey A. , Mullighan Charles G. , Burke Michael J. , Luskin Marlise R. , Mar Brenton G. , Jacobson Matthew P. , Harris Marian H. , Stegmaier Kimberly , Place Andrew E. , Pikman Yana
Published: November 2023

Hydrogen bonding of PDGFRA p.D842.
Supplementary Table 4 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Authors: Paolino Jonathan , Dimitrov Boris , Apsel Winger Beth , Sandoval-Perez Angelica , Rangarajan Amith Vikram , Ocasio-Martinez Nicole , Tsai Harrison K. , Li Yuting , Robichaud Amanda L. , Khalid Delan , Hatton Charlie , Gillani Riaz , Polonen Petri , Dilig Anthony , Gotti Giacomo , Kavanagh Julia , Adhav Asmani A. , Gow Sean , Tsai Jonathan , Li Yen Der , Ebert Benjamin L. , Van Allen Eliezer M. , Bledsoe Jacob , Kim Annette S. , Tasian Sarah K. , Cooper Stacy L. , Cooper Todd M. , Hijiya Nobuko , Sulis Maria Luisa , Shukla Neerav N. , Magee Jeffrey A. , Mullighan Charles G. , Burke Michael J. , Luskin Marlise R. , Mar Brenton G. , Jacobson Matthew P. , Harris Marian H. , Stegmaier Kimberly , Place Andrew E. , Pikman Yana
Published: November 2023

Treatment history for patient 146.
Supplementary Table S4 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Characteristics of control cohort
Supplementary Table S3 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Adverse events
Supplementary Table 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Authors: Paolino Jonathan , Dimitrov Boris , Apsel Winger Beth , Sandoval-Perez Angelica , Rangarajan Amith Vikram , Ocasio-Martinez Nicole , Tsai Harrison K. , Li Yuting , Robichaud Amanda L. , Khalid Delan , Hatton Charlie , Gillani Riaz , Polonen Petri , Dilig Anthony , Gotti Giacomo , Kavanagh Julia , Adhav Asmani A. , Gow Sean , Tsai Jonathan , Li Yen Der , Ebert Benjamin L. , Van Allen Eliezer M. , Bledsoe Jacob , Kim Annette S. , Tasian Sarah K. , Cooper Stacy L. , Cooper Todd M. , Hijiya Nobuko , Sulis Maria Luisa , Shukla Neerav N. , Magee Jeffrey A. , Mullighan Charles G. , Burke Michael J. , Luskin Marlise R. , Mar Brenton G. , Jacobson Matthew P. , Harris Marian H. , Stegmaier Kimberly , Place Andrew E. , Pikman Yana
Published: November 2023

Description of the overall representativeness of study participants compared with previously reported studies.
Supplementary Table S1 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Representativeness of study population
Supplementary Figure S7 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Supplemental figure S7: Progression free survival estimates of vaccine treated cohort (N=14) compared with biospecimen control cohort and large institutional cohort
Supplementary Figure S5 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Supplemental Figure S5. Burden of CD138+ survivin expressing plasma cells in the baseline bone marrow biopsies and relationship with adaptive and humoral responses
Supplementary Figure S3 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Supplemental Figure S3: Survivin gene expression and relationship with progression free and overall survival in transplant eligible patients (institution data)
Supplementary Figure S1 from Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma
Authors: Freeman Ciara L. , Atkins Reginald , Varadarajan Indumathy , Menges Meghan , Edelman Jeffrey , Baz Rachid , Brayer Jason , Castaneda Puglianini Omar , Ochoa-Bayona Jose Leonel , Nishihori Taiga , Shain Kenneth H. , Shah Bijal , Chen Dung Tsa , Kelley Linda , Coppola Domenico , Alsina Melissa , Antonia Scott , Anasetti Claudio , Locke Frederick L.
Published: November 2023

Supplemental Figure S1: CONSORT Diagram
Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Hanna Glenn J. , Ahn Myung-Ju , Muzaffar Jameel , Keam Bhumsuk , Bowles Daniel W. , Wong Deborah J. , Ho Alan L. , Kim Sung-Bae , Worden Francis , Yun Tak , Meng Xianzhang , Van Tornout Jan M. , Conlan Maureen G. , Kang Hyunseok
Published: November 2023

AbstractPurpose:
This open-label, single-arm, phase II study evaluated the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
Patients and Methods:
Eligible patients had confirmed disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) with ≥20% increase in radiologically or clinically measurable lesions or appearance of new lesions within the preceding 6 months. Patients received oral rivoceranib 700 mg once daily. Primary outcomes were objective response rate (ORR) by investigator review and by blinded independent review committee (BIRC).
Results:
Eighty patients were enrolled and 72 were efficacy evaluable. Seventy-four patients had distant metastases and 49 received prior systemic treatment (14 received VEGFR TKIs). Per investigator and BIRC, respectively, ORR was 15.3% [95% confidence interval (95% CI), 7.9–25.7] and 9.7% (95% CI, 4.0–19.0); median duration of response was 14.9 months (95% CI, 4.9–17.3) and 7.2 months (95% CI, 3.5–8.4); and median progression-free survival was 9.0 months (95% CI, 7.3–11.5) and 9.0 months (95% CI, 7.7–11.5). Grade ≥3 treatment-related adverse events occurred in 56 patients (70.0%); the most common were hypertension (34, 42.5%) and stomatitis (6, 7.5%). Four grade 5 events occurred with one attributed to rivoceranib (epistaxis). Sixty-eight patients (85.0%) had ≥1 dose modifications and 16 patients (20.0%) discontinued rivoceranib for toxicity.
Conclusions:
In patients with progressing R/M ACC, rivoceranib demonstrated antitumor activity and a manageable safety profile consistent with other VEGFR TKIs.
Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Authors: Solta Anna , Boettiger Kristiina , Kovács Ildikó , Lang Christian , Megyesfalvi Zsolt , Ferk Franziska , Mišík Miroslav , Hoetzenecker Konrad , Aigner Clemens , Kowol Christian R. , Knasmueller Siegfried , Grusch Michael , Szeitz Beáta , Rezeli Melinda , Dome Balazs , Schelch Karin
Published: November 2023

AbstractPurpose:
Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.
Experimental Design:
The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.
Results:
Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.
Conclusions:
In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.
Data from Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Authors: Friedman Claire F. , Ravichandran Vignesh , Miller Kathryn , Vanderbilt Chad , Zhou Qin , Iasonos Alexia , Vivek Malavika , Mishra Pamela , Leitao Mario M. , Broach Vance , Sonoda Yukio , Kyi Chrisann , Zamarin Dmitriy , O'Cearbhaill Roisin E. , Konner Jason , Berger Michael F. , Weigelt Britta , Momeni Boroujeni Amir , Park Kay J. , Aghajanian Carol , Solit David B. , Donoghue Mark T.A.
Published: November 2023

AbstractPurpose:
Tumor genomic profiling is increasingly used to guide treatment strategy in patients with cancer. We integrated tumor genomic, clinical demographic, and treatment response data to assess how prospective tumor-normal sequencing impacted treatment selection in patients with cervical cancer.
Experimental Design:
Cervical cancers were prospectively analyzed using the MSK-IMPACT (Memorial Sloan Kettering Cancer Center – Integrated Mutation Profiling of Actionable Cancer Targets) next-generation sequencing panel. Clinical data, including histology, stage at diagnosis, treatment history, clinical trial enrollment and outcomes, date of last follow-up, and survival status were obtained from medical records.
Results:
A total of 177 patients with cervical cancer (squamous, 69; endocervical adenocarcinoma, 50; gastric type, 22; adenosquamous, 21; and other, 15) underwent MSK-IMPACT testing. The most prevalent genomic alterations were somatic mutations or amplifications in PIK3CA (25%), ERBB2 (12%), KMT2C (10%), and KMT2D (9%). Furthermore, 13% of patients had high tumor mutational burden (TMB >10 mut/Mb), 3 of which were also microsatellite instability–high (MSI-H). Thirty-seven percent of cases had at least one potentially actionable alteration designated as a level 3B mutational event according to the FDA-recognized OncoKB tumor mutation database and treatment classification system. A total of 30 patients (17%) were enrolled on a therapeutic clinical trial, including 18 (10%) who were matched with a study based on their MSK-IMPACT results. Twenty patients (11%) participated in an immune checkpoint inhibition study for metastatic disease; 2 remain progression free at >5 years follow-up.
Conclusions:
Tumor genomic profiling can facilitate the selection of targeted/immunotherapies, as well as clinical trial enrollment, for patients with cervical cancer.